VETARYS and Antigenesis Biologics have announced a research collaboration to develop a combination immunotherapy targeting solid tumors in dogs. The investigational treatment aims to improve cancer care options through a subcutaneous therapy that could potentially be administered by primary care veterinarians.
Familiar Therapeutics has launched with $5 million in seed funding to develop veterinary medicines based on advances in human drug research. The company has established 13 programs targeting diseases in dogs and cats, with its first clinical study focused on canine hemangiosarcoma scheduled to begin this fall at the University of Illinois.
Wedgewood Pharmacy has announced a nationwide recall of certain compounded veterinary medications due to concerns about the reliability of laboratory testing data that could result in products containing too much or too little active medication. The company has received 98 complaints, including seven serious complaints, and is advising affected customers to stop using recalled products.
Zoetis has received FDA approval for Convenia RTU for Dogs, a higher-concentration injectable antibiotic that provides up to 14 days of treatment for susceptible bacterial skin infections. The new formulation reduces injection volume, making treatment more practical for medium and large dogs.
Kemin Industries has expanded the approved uses of its KemTRACE Chromium feed ingredient following FDA review of chromium propionate for broiler breeder chickens and laying hens. The regulatory milestone adds two poultry production categories to the ingredient’s established uses across livestock and poultry species.
Scottish veterinary oncology company Kyrexa has received two FDA Minor Use/Minor Species (MUMS) designations for rimcazole, an investigational oral cancer therapy targeting canine oral melanoma and cutaneous or oral squamous cell carcinoma. The designations support the drug’s regulatory development as a potential at-home treatment option for dogs with difficult-to-treat cancers.
Boehringer Ingelheim has introduced an FDA-approved, quarterable Snap-Tab design for PREVICOX (firocoxib) chewable tablets, allowing veterinarians to tailor dosing more precisely for dogs weighing as little as seven pounds. The redesigned tablets also offer storage and packaging improvements intended to reduce product waste.
A peer-reviewed laboratory study funded by Zoetis found that Simparica Trio-treated dogs had significantly lower average heartworm counts than NexGard Plus-treated dogs following experimental challenge with the macrocyclic lactone-resistant Dirofilaria immitis ZoeLA isolate.
Cronus Pharma has launched Florfinasone Otic, an FDA-approved fixed-combination therapy for treating canine otitis externa associated with susceptible strains of Malassezia pachydermatis and Staphylococcus pseudintermedius.
Bimeda has expanded its anti-parasitic portfolio with MoxiSolv Pour-On, the first available FDA-approved bioequivalent alternative to Elanco’s Cydectin Pour-On. The moxidectin product is labeled for beef and dairy cattle of all ages, including lactating dairy cows.
Sign up for free to receive the latest veterinary news, product announcements, and industry developments.